Cross-Sector entity
Of the tracked stories, 3 of 3 also mention FDA, the most common co-covered peer. Across a 12-day span, the pace is roughly 1.8 stories per week. The busiest single day carried 2. fda-approval accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder.
3 verified stories tracked
Last mentioned: Mar 7, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention FDA, the most common co-covered peer. Across a 12-day span, the pace is roughly 1.8 stories per week. The busiest single day carried 2. fda-approval accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 4.7 original sources on average. CBER appears in 3 tracked Cross-Sector stories published from February 24, 2026 through March 7, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CBER. Shared-story counts are live from our verified record — not editorial picks.
Final Departure
Official announcement of Marks leaving the agency for the second time.
Formal Proposal
FDA formally proposes the new customized drug approval system for ultra-rare diseases.
BGTC Pilot Completion
The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
Initial Friction
Reports surface of Marks considering resignation amid administrative policy shifts.
Draft Guidance Issued
FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
PREVENT Act Passed
Congress directs FDA to establish a framework for platform technology designations.
Operation Warp Speed
Plays a central role in the emergency use authorizations for COVID-19 vaccines.
Appointed Director
Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
Joins FDA
Dr. Peter Marks joins the FDA as Deputy Director of CBER.
The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
Source: mymotherlode.com · journalgazette.net
The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
